Kevin Joseph Fitzgerald Sells 12,128 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 12,128 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the completion of the sale, the executive vice president directly owned 21,264 shares in the company, valued at approximately $9,615,155.52. The trade was a 36.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Thursday, October 2nd, Kevin Joseph Fitzgerald sold 2,441 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $452.05, for a total transaction of $1,103,454.05.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $436.38 on Friday. The company has a market capitalization of $57.65 billion, a price-to-earnings ratio of -176.67 and a beta of 0.30. The stock’s 50 day moving average is $457.30 and its 200-day moving average is $389.74. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55.

Wall Street Analyst Weigh In

ALNY has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. Needham & Company LLC raised their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. UBS Group boosted their target price on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a report on Friday, August 1st. Chardan Capital raised their price target on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Finally, Royal Bank Of Canada boosted their price objective on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a report on Friday, September 19th. Twenty-three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $482.17.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Root Financial Partners LLC bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at about $25,000. SVB Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter worth about $27,000. Salomon & Ludwin LLC bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $29,000. Finally, Atlantic Union Bankshares Corp purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth about $30,000. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.